EP300 and precursor B-cell acute lymphoblastic leukemia: First, we did not explain why EP300-ZNF384 positive B-ALL cells are selectively sensitive to doxorubicin; thus, further research should investigate the mechanism of doxorubicin action on EP300-ZNF384 positive B-ALL cells.